Chemotherapy and anti-hormonal therapies are the most common treatments for non-organ-confined prostate cancer (PCa). However, the effectiveness of these therapies is limited, thus necessitating the development of alternative approaches. The present study focused on analyzing the role of pterostilbene (PTER)-isothiocyanate (ITC) conjugate – a novel class of hybrid compound synthesized by appending an ITC moiety on PTER backbone – in regulating the functions of androgen receptor (AR), thereby causing apoptosis of PCa cells. The conjugate molecule caused 50% growth inhibition (IC50) at 40±1.12 and 45±1.50 μM in AR positive (LNCaP) and negative (PC-3) cells, respectively. The reduced proliferation of PC-3 as well as LNCaP cells by conjugate correlated with accumulation of cells in G2/M phase and induction of caspase dependent apoptosis. Both PI3K/Akt and MAPK/ERK pathways played an important and differential role in conjugate-induced apoptosis of these PCa cells. While the inhibitor of Akt (A6730) or Akt-specific small interference RNA (siRNA) greatly sensitized PC-3 cells to conjugate-induced apoptosis, on the contrary, apoptosis was accelerated by inhibition of ERK (by PD98059 or ERK siRNA) in case of LNCaP cells, both ultimately culminating in the expression of cleaved caspase-3 protein. Moreover, anti-androgenic activity of the conjugate was mediated by decreased expression of AR and its co-activators (SRC-1, GRIP-1), thus interfering in their interactions with AR. All these data suggests that conjugate-induced inhibition of cell proliferation and induction of apoptosis are partly mediated by the down regulation of AR, Akt, and ERK signaling. These observations provide a rationale for devising novel therapeutic approaches for treating PCa by using conjugate alone or in combination with other therapeutics.
References
[1]
Jemal A, Siegel R, Ward E, Xu J (2010) Cancer statistics. CA Cancer J Clin 60: 277–300. doi: 10.3322/caac.20073
[2]
Taplin ME, Balk SP (2004) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483–490. doi: 10.1002/jcb.10653
[3]
Ho SM (2004) Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 91: 491–503. doi: 10.1002/jcb.10759
[4]
Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein- 3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346–1353. doi: 10.1016/s0140-6736(04)16044-3
[5]
Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagini R, et al. (2005) Cancer of the prostate. Crit Rev Oncol Hematol 56: 379–96. doi: 10.1016/j.critrevonc.2005.03.010
[6]
Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276–308. doi: 10.1210/er.2002-0032
Heinlein CA, Chang C (2002) Androgen receptor (AR) co-regulators: an overview. Endocr Rev 23: 175–200. doi: 10.1210/edrv.23.2.0460
[9]
Gan Y, Shi C, Inge L, Hibner M, Balducci J, et al. (2010) Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 29: 4947–4958. doi: 10.1038/onc.2010.240
[10]
Wen Y, Hu MCT, Makino K, Spohn B, Bartholomeusz G, et al. (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841–5.
[11]
Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, et al. (2002) Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 113: 71S–88S. doi: 10.1016/s0002-9343(01)00995-0
[12]
Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL (2011) Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 68(3): 593–601. doi: 10.1007/s00280-010-1525-4
[13]
Alosi JA, McDonald DE, Schneider JS, Privette AR, McFadden DW (2010) Pterostilbene inhibits breast cancer in vitro through mitochondrial depolarization and induction of caspase-dependent apoptosis. J Surg Res 161: 195–201. doi: 10.1016/j.jss.2009.07.027
[14]
Chakraborty A, Gupta N, Ghosh K, Roy P (2010) In vitro evaluation of the cytotoxic, anti-proliferative and anti-oxidant properties of pterostilbene isolated from Pterocarpus marsupium. Toxicol In Vitro 24: 1215–1228. doi: 10.1016/j.tiv.2010.02.007
[15]
Pan MH, Lin YT, Lin CL, Wei CS, Ho CT, et al. (2011) Suppression of Heregulin-b1/HER2-modulated invasive and aggressive phenotype of breast carcinoma by pterostilbene via inhibition of matrix metalloproteinase-9, p38 kinase cascade and Akt activation. Evid Based Complement Alternat Med: 1–12.
[16]
Wang TT, Schoene NW, Kim YS, Mizuno CS, Rimando AM (2010) Differential effects of resveratrol and its naturally occurring ethylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells. Mol Nutr Food Res 54: 335–44. doi: 10.1002/mnfr.200900143
[17]
Lin VCH, Tsai YC, Lin JN, Fan LL, Pan MH, et al. (2012) Activation of AMPK by pterostilbene suppresses lipogenesis and cell-cycle progression in p53 positive and negative human prostate cancer cells. J Agric Food Chem 60: 6399–6407. doi: 10.1021/jf301499e
[18]
Li K, Dias SJ, Rimando AM, Dhar S, Mizuno CS, et al. (2013) Pterostilbene acts through Metastasis-Associated Protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PloS one 8 (3): e57542. doi: 10.1371/journal.pone.0057542
[19]
Cavell BE, Syed Alwi SS, Donlevy A, Packham G (2011) Anti-angiogenic effects of dietary isothiocyanates: mechanisms of action and implications for human health. Biochem Pharmacol 81: 327–336. doi: 10.1016/j.bcp.2010.10.005
[20]
Keum YS, Jeong WS, Kong AN (2004) Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat Res 555: 191–202. doi: 10.1016/j.mrfmmm.2004.05.024
[21]
Wang L, Liu D, Ahmed T, Chung FL, Conaway CC, et al. (2004) Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. Int J Oncol 24: 187–192. doi: 10.3892/ijo.24.1.187
[22]
Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A, et al. (2002) Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. Int J Oncol 20: 631–636. doi: 10.3892/ijo.20.3.631
[23]
Wang LG, Liu XM, Chiao JW (2006) Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. Carcinogenesis 10: 2124–32. doi: 10.1093/carcin/bgl075
[24]
Xiao D, Singh SV (2002) Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 62: 3615–3619.
[25]
Nikhil K, Sharan S, Chakraborty A, Bodipati N, Krishna Peddinti R, et al. (2013) Role of isothiocyanate conjugate of pterostilbene on the inhibition of MCF-7 cell proliferation and tumor growth in Ehrlich ascitic cell induced tumor bearing mice. Exp Cell Res 320: 311–328. doi: 10.1016/j.yexcr.2013.10.015
[26]
Yuan H, Gong A, Young CY (2005) Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26: 793–801. doi: 10.1093/carcin/bgi021
[27]
Chakraborty A, Bodhipati N, Demonacos MK, Peddinti R, Ghosh K, et al. (2012) Long term induction by pterostilbene results in autophagy and cellular differentiation in MCF-7 cells via ROS dependent pathway. Mol. Cell. Endocrinol 355: 25–40. doi: 10.1016/j.mce.2012.01.009
[28]
Fimognari C, Lenzi M, Hrelia P (2009) Apoptosis induction by sulfur-containing compounds in malignant and nonmalignant human cells. Environ Mol Mutagen 50(3): 171–189. doi: 10.1002/em.20447
[29]
Wu X, Zhou QH, Xu K (2009) Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin 30(5): 501–512. doi: 10.1038/aps.2009.50
[30]
Fimognari C, Nüsse M, Berti F, Iori R, Cantelli-Forti G, et al. (2004) Isothiocyanates as novel cytotoxic and cytostatic agents: molecular pathway on human transformed and non-transformed cells. Biochem Pharmacol 68(6): 1133–1138. doi: 10.1016/j.bcp.2004.03.044
[31]
Fimognari C, Turrini E, Ferruzzi L, Lenzi M, Hrelia P (2012) Natural isothiocyanates: Genotoxic potential versus chemoprevention. Mutat Res 750(2): 107–131. doi: 10.1016/j.mrrev.2011.12.001
[32]
Jasiński M, Jasińska L, Ogrodowczyk M (2013) Resveratrol in prostate diseases–a short review. Angiogenesis 56, 60.
[33]
Carter LG, D’Orazio JA, Pearson KJ (2014) Resveratrol and cancer: a focus on in vivo evidence. Endocr Relat Cancer, doi: –10.1530/ERC-13–0171.
[34]
Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 network. J Biol Chem 273: 1–4. doi: 10.1074/jbc.273.1.1
[35]
Sheikh MS, Fornace AJ (2000) Role of p53 family members in apoptosis. J Cell Physiol 182: 171–181. doi: 10.1002/(sici)1097-4652(200002)182:2<171::aid-jcp5>3.0.co;2-3
[36]
Wang Y, Ji P, Liu J, Broaddus RR, Xue F, et al. (2009) Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 8: 8. doi: 10.1186/1476-4598-8-8
[37]
Hui G, Xuesong O, Whitney AB, William LG, Michael MS, et al. (2006) Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 103: 14477–14482. doi: 10.1073/pnas.0606836103
[38]
Addanki PK, Gretchen EG, Rita G, Rajendran VR, William LA, et al. (2003) 4-Hydroxy-3-methoxybenzoic acid methyl ester: A curcumin derivative targets Akt/NFκB cell survival signaling pathway: Potential for prostate cancer management. Neoplasia 5(3): 255–266. doi: 10.1016/s1476-5586(03)80057-x
[39]
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, et al. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193–204. doi: 10.1016/j.ctrv.2003.07.007
[40]
del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687–689. doi: 10.1126/science.278.5338.687
Caraglia M, Marra M, Leonetti C, Meo G, D’Alessandro AM, et al. (2007) R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 211: 533–543. doi: 10.1002/jcp.20960
[44]
Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, et al. (2003) ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107: 478–485. doi: 10.1002/ijc.11413
[45]
Grigoryev DN, Long BJ, Njar VC, Brodie AH (2000) Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J Steroid Biochem Mol Biol 75: 1–10. doi: 10.1016/s0960-0760(00)00131-x
[46]
Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, et al. (1999) From HER2/Neu signal cascade to androgen receptor and its co-activators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96: 5458–5463. doi: 10.1073/pnas.96.10.5458
[47]
Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, et al. (2001) From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 98: 3018–3023. doi: 10.1073/pnas.061305498
[48]
Harada N, Murata Y, Yamaji R, Miura T, Inui H, et al. (2007) Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol 53: 556–560. doi: 10.3177/jnsv.53.556
[49]
Ren F, Zhang S, Mitchell SH, Butler R, Young CY (2000) Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19: 1924–1932. doi: 10.1038/sj.onc.1203511
[50]
Chiu FL, Lin JK (2008) Down regulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 68(1): 61–71. doi: 10.1002/pros.20690
[51]
Liu C, Nagalakshmi N, Ramakumar T, Jae YC, Wei L, et al. (2011) Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer 2: 151–159. doi: 10.1177/1947601911409744
[52]
Cha TL, Lin QL, Chen CT, Wen Y, Hung MC (2005) Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 65: 2287–95. doi: 10.1158/0008-5472.can-04-3250
[53]
Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF, et al. (2005) Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells. Carcinogenesis 26: 1896–904. doi: 10.1093/carcin/bgi155
[54]
Papaioannou M, Reeb C, Asim M, Dotzlaw H, Baniahmad A (2005) Co-activator and co-repressor interplay on the human androgen receptor. Andrologia 37: 211–212. doi: 10.1111/j.1439-0272.2005.00690.x
Agoulnik IU, Vaid A, Bingman WE, Erdeme H, Frolov A, et al. (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65: 7959–67.
[57]
O？ate SA, Tsai SY, Tsai MJ, O’Malley BW (1995) Sequence and characterization of a co-activator for the steroid hormone receptor superfamily. Science 270: 1354–1357. doi: 10.1126/science.270.5240.1354
[58]
Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, et al. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315–4319.
